Literature DB >> 12215844

Favourable mutation test outcomes for individuals at risk for Huntington disease change the perspectives of first-degree relatives.

Benno Bonke1, Aad Tibben, Dick Lindhout, Theo Stijnen.   

Abstract

In mutation testing for Huntington disease, an autosomal dominant hereditary late-onset disorder, unfavourable test outcomes in at-risk individuals provide important information about other family members at risk. On the other hand, common counselling practice considers favourable outcomes as non-informative for at-risk relatives, except for the offspring of the tested individual. We shall show, however, that favourable outcomes also change the perspectives for the tested individual's first-degree relatives at risk. In the case of a (prospective) parent originally at 50% risk, and with n equalling the number of children or fetuses identified as non-carriers, the probability of being a non-carrier equals 2 (n)/(2 (n)+1) for the at-risk parent, providing that none of the offspring of this parent has been identified as a carrier. Likewise, the probability of being a non-carrier equals (2 (n+1)+1)/(2 (n+1)+2) for the (future) siblings of the tested individual. These changes in probabilities are important for individuals who are considering prenatal or presymptomatic DNA-testing for autosomal dominant hereditary late-onset disorders, such as Huntington disease and hereditary forms of cancer (BRCA1/2, FAP, HNPCC). Consequences can be far reaching in the case of pregnancies, where the risk of miscarriage after a prenatal test is 1%-2%. Parents initially at 50% risk may consider not having a prenatal test in successive pregnancies, knowing that favourable test results in previous pregnancies have considerably reduced their personal risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12215844     DOI: 10.1007/s00439-002-0764-9

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  2 in total

1.  Bayesian risk assessment in genetic testing for autosomal dominant disorders with age-dependent penetrance.

Authors:  Shuji Ogino; Robert B Wilson; Bert Gold; Pamela Flodman
Journal:  J Genet Couns       Date:  2007-02-13       Impact factor: 2.537

2.  Estimating decreased risks for Huntington disease without a test.

Authors:  Reinier Timman; Benno Bonke; Theo Stijnen; Aad Tibben; Anneke Maat-Kievit
Journal:  Eur J Epidemiol       Date:  2008-01-30       Impact factor: 8.082

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.